A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan
Japan's adult respiratory vaccination programs generate substantial socioeconomic returns, strengthening public health, healthcare resilience, and workforce productivity. Increasing uptake across the population can generate significantly higher NBs. Realizing these benefits requires addressing vaccine uptake barriers and enhancing public investment.
Authors
- Jeffrey Vietri (ORCID: https://orcid.org/0000-0002-5610-3098)
- Simon Brassel (ORCID: https://orcid.org/0000-0001-7574-9671)
- Tianyan Hu (ORCID: https://orcid.org/0009-0004-2660-8871)
- Kazumasa Kamei (ORCID: https://orcid.org/0000-0001-7220-5142)
- Diana Mendes (ORCID: https://orcid.org/0000-0002-1672-4906)
- Jingyan Yang (ORCID: https://orcid.org/0000-0001-5523-649X)
- Lotte Steuten (ORCID: https://orcid.org/0000-0002-5688-236X)
- Melanie Napier
- Shuhei Ito (ORCID: https://orcid.org/0000-0003-0289-7766)
- Claud Theakston
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Office Of Health Economics (GB)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1080/14760584.2025.2536092
- Citations
- 2
- Primary Topic
- Vaccine Coverage and Hesitancy
- Type
- article
- Field-Weighted Citation Impact
- 4.33
Funders
- Pfizer